Combined modality therapy in pancreatic adenocarcinoma: review and updates on a controversial issue.
Curr Pharm Des
; 20(42): 6697-701, 2014.
Article
em En
| MEDLINE
| ID: mdl-25341941
ABSTRACT
Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Adenocarcinoma
Limite:
Humans
Idioma:
En
Revista:
Curr Pharm Des
Assunto da revista:
FARMACIA
Ano de publicação:
2014
Tipo de documento:
Article